Company profile
VitaSpring Biomedical Co. Ltd.
OTC: VSBC · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
18DFH 14DQ 24GM —SS 23
v0.1 · 55/100 weight · provisional
↑ Piotroski F, disclosure history · ↓ workforce scale, filing timeliness
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$415.4k
Employees
1
as of 2026-08-25
Market cap
$2.3M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02026
Net income-$415.4k-$415.4k2026
Operating income-$385.4k-$385.4k2026
Total assets$14.7k$14.7k2026
Liabilities$4.4M$4.4M2026
Equity-$4.4M-$4.4M2026
Revenue trend
FY2019 – FY2026 · USD
FY19
FY21
FY21
FY21
FY23
FY24
FY25
FY26
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is VitaSpring Biomedical Co. Ltd.’s revenue?
VitaSpring Biomedical Co. Ltd. booked $0 in FY2026 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Eco-Growth Strategies Inc.——Indo Global Exchange(s) PTE, Ltd.——BioVaxys Technology Corp.——Psyence Group Inc.——Lifeline Biotechnologies, Inc.——Nu-Med Plus, Inc.23DNeighbors
Orange →Key facts
CEOSsu-Chuan Lai
SectorHealthcare
IndustryBiotechnology
HeadquartersIrvine, CA
ExchangeOTC: VSBC
Employees1
IPO date2019-11-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.